MDxHealth CEO to Keynote at Biomarkers from Research to Clinic Conference
Complete the form below to unlock access to ALL audio articles.
MDxHealth SA has announced that its CEO, Dr Jan Groen, will deliver a keynote presentation at the Biomarkers from Research to Clinic, Prognostic, Predictive & Point-of-Care Conference at 13:15 PST on January 15 in San Diego, CA, USA.
The presentation, "Epigenetic Biomarkers in Oncology", will highlight the development and commercialization of epigenetic diagnostic tests, several of which are now commercially available and used routinely in clinical practice.
All cancers show epigenetic changes. Measuring the epigenetic changes associated with specific genes can help guide physicians in the management of a patient's disease. With continued market adoption of the ConfirmMDx® for Prostate Cancer test, the inclusion of PredictMDx® for Glioblastoma into the NCCN guidelines, and the launch of Cologuard® for colon cancer by licensee Exact Sciences, there are now three successful diagnostic tests on the U.S. market using MDxHealth's epigenetic technology and biomarkers.
